Vyome Holdings, Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Vyome Holdings, Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $319.7K | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $256.9K | Mar 18, 2026 |
| FY2018 | Dec 31, 2018 | $2.04M | Feb 22, 2019 |
| FY2018 | Sep 30, 2018 | $2.99M | Feb 22, 2019 |
| FY2018 | Jun 30, 2018 | $2.73M | Feb 22, 2019 |
| FY2018 | Mar 31, 2018 | $1.35M | Feb 22, 2019 |
| FY2018 | Dec 31, 2017 | $3.69M | Feb 22, 2019 |
| FY2018 | Sep 30, 2017 | $2.79M | Feb 22, 2019 |
| FY2018 | Jun 30, 2017 | $1.96M | Feb 22, 2019 |
| FY2018 | Mar 31, 2017 | $1.47M | Feb 22, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $8.01M | Apr 4, 2025 |
| FY2024 | Dec 31, 2023 | $8.68M | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | $11.24M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $13.60M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $11.30M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $3.28M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $9.10M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $9.91M | Feb 22, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $218.8K | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $195.0K | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $5.55M | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | $6.80M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $8.35M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $6.26M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $331.0K | Mar 12, 2021 |
| FY2018 | Dec 31, 2018 | $532.0K | Feb 22, 2019 |
| FY2018 | Sep 30, 2018 | $1.57M | Feb 22, 2019 |
| FY2018 | Jun 30, 2018 | $1.00M | Feb 22, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.26M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($1.45M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($11.39M) | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | ($46.21M) | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | ($12.19M) | Apr 17, 2023 |
| FY2022 | Jun 30, 2022 | ($9.44M) | Apr 17, 2023 |
| FY2022 | Mar 31, 2022 | ($8.12M) | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | ($63.15M) | Apr 17, 2023 |
| FY2022 | Sep 30, 2021 | ($17.13M) | Apr 17, 2023 |
| FY2022 | Jun 30, 2021 | ($3.89M) | Apr 17, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.45M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($1.01M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($15.38M) | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | ($46.35M) | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | ($12.30M) | Apr 17, 2023 |
| FY2022 | Jun 30, 2022 | ($9.24M) | Apr 17, 2023 |
| FY2022 | Mar 31, 2022 | ($8.11M) | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | ($57.88M) | Apr 17, 2023 |
| FY2022 | Sep 30, 2021 | ($14.42M) | Apr 17, 2023 |
| FY2022 | Jun 30, 2021 | ($3.69M) | Apr 17, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $588.3K | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $285.4K | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $2.32M | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | $2.54M | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | $583.0K | Apr 17, 2023 |
| FY2022 | Jun 30, 2022 | $747.0K | Apr 17, 2023 |
| FY2022 | Mar 31, 2022 | $745.0K | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | $2.37M | Apr 17, 2023 |
| FY2022 | Sep 30, 2021 | $1.43M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $3.50M | Apr 8, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.37M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $898.6K | Mar 18, 2026 |
| FY2023 | Dec 31, 2023 | $7.55M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $14.09M | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | $2.61M | Apr 17, 2023 |
| FY2022 | Jun 30, 2022 | $4.64M | Apr 17, 2023 |
| FY2022 | Mar 31, 2022 | $4.69M | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | $8.89M | Apr 17, 2023 |
| FY2022 | Sep 30, 2021 | $3.25M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $4.69M | Apr 8, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.75M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($614.1K) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($16.96M) | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | ($21.90M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($15.38M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($8.55M) | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | ($22.87M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | ($29.43M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | ($30.62M) | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | ($19.37M) | Mar 5, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $171.0K | Mar 12, 2021 |
| FY2020 | Dec 31, 2019 | $194.0K | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $1.28M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $1.04M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $352.0K | Mar 5, 2018 |
| FY2017 | Dec 31, 2015 | $139.0K | Mar 5, 2018 |
| FY2016 | Dec 31, 2014 | $268.0K | Feb 23, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.50M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $1.38M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $10.66M | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | $11.14M | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | $26.49M | Apr 17, 2023 |
| FY2022 | Jun 30, 2022 | $40.36M | Apr 17, 2023 |
| FY2022 | Mar 31, 2022 | $45.62M | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | $52.53M | Apr 17, 2023 |
| FY2022 | Sep 30, 2021 | $90.79M | Apr 17, 2023 |
| FY2022 | Jun 30, 2021 | $120.01M | Apr 17, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.74M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $5.77M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $4.00M | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | $7.48M | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | $7.53M | Apr 17, 2023 |
| FY2022 | Jun 30, 2022 | $9.58M | Apr 17, 2023 |
| FY2022 | Mar 31, 2022 | $8.66M | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | $8.20M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $22.57M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $4.54M | Mar 12, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($253.0K) | Apr 4, 2025 |
| FY2024 | Dec 31, 2023 | $6.66M | Apr 4, 2025 |
| FY2024 | Dec 31, 2022 | $3.66M | Apr 4, 2025 |
| FY2022 | Sep 30, 2022 | $18.95M | Apr 17, 2023 |
| FY2022 | Jun 30, 2022 | $30.78M | Apr 17, 2023 |
| FY2022 | Mar 31, 2022 | $36.96M | Apr 17, 2023 |
| FY2023 | Dec 31, 2021 | $44.33M | Apr 1, 2024 |
| FY2022 | Sep 30, 2021 | $79.31M | Apr 17, 2023 |
| FY2022 | Jun 30, 2021 | $58.13M | Apr 17, 2023 |
| FY2022 | Mar 31, 2021 | $12.71M | Apr 17, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2021 | $22.95M | Apr 17, 2023 |
| FY2022 | Jun 30, 2021 | $23.52M | Apr 17, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($87.56M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($55.42M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($635.57M) | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | ($624.19M) | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | ($607.72M) | Apr 17, 2023 |
| FY2022 | Jun 30, 2022 | ($595.53M) | Apr 17, 2023 |
| FY2022 | Mar 31, 2022 | ($586.09M) | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | ($577.97M) | Apr 17, 2023 |
| FY2022 | Sep 30, 2021 | ($540.72M) | Apr 17, 2023 |
| FY2022 | Jun 30, 2021 | ($523.59M) | Apr 17, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.98M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $101.9K | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $4.46M | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | $3.86M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $22.77M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $2.96M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $14.06M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $21.19M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $21.11M | Feb 22, 2019 |
| FY2018 | Dec 31, 2016 | $72.98M | Feb 22, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2020 | $13.32M | Apr 8, 2022 |
| FY2018 | Dec 31, 2018 | $9.93M | Feb 22, 2019 |
| FY2017 | Dec 31, 2017 | $9.92M | Mar 5, 2018 |
| FY2016 | Dec 31, 2016 | $9.88M | Feb 23, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | (6,001) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | (110) | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | (108) | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | (27) | Apr 17, 2023 |
| FY2022 | Jun 30, 2022 | (24) | Apr 17, 2023 |
| FY2022 | Mar 31, 2022 | (21) | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | (288) | Apr 17, 2023 |
| FY2022 | Sep 30, 2021 | (50) | Apr 17, 2023 |
| FY2022 | Jun 30, 2021 | (42) | Apr 17, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | (6,001) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | (110) | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | (108) | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | (27) | Apr 17, 2023 |
| FY2022 | Jun 30, 2022 | (24) | Apr 17, 2023 |
| FY2022 | Mar 31, 2022 | (21) | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | (288) | Apr 17, 2023 |
| FY2022 | Sep 30, 2021 | (50) | Apr 17, 2023 |
| FY2022 | Jun 30, 2021 | (42) | Apr 17, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5.92M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | 404,437 | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | 519,219 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 356,641 | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 3.49M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | 7.72M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | 2.35M | Feb 27, 2020 |
| FY2020 | Dec 26, 2018 | 2.33M | Mar 12, 2021 |
| FY2018 | Dec 31, 2017 | 17.50M | Feb 22, 2019 |